Alterity Therapeutics Ltd (ATHE)
NASDAQ:ATHE
Want to see ATHE full AI Analyst Report?
Top Page
Alterity Therapeutics
(NASDAQ:ATHE)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.00
▲(12.68% Upside)
Action:Reiterated
Date:06/10/26
The score is primarily held down by weak financial performance (ongoing losses and negative cash flows) and an earnings-based valuation that reflects unprofitability. Technicals provide only modest support, with prices slightly above moving averages but mixed momentum signals.
Positive Factors
High gross margins
Sustained gross margins above 90% indicate highly favorable unit economics and efficient cost structure for current activities. That margin cushion supports future scale-up economics, improving the odds that increased revenue from trials or partnerships can translate into positive operating leverage over time.
Negative Factors
Persistent unprofitability
Ongoing net losses and negative EBIT margins show the company is not yet profitable and must rely on external funding. Persistent unprofitability limits reinvestment capacity, increases dilution risk for equity holders, and constrains strategic flexibility during the multi-year drug development cycle.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins above 90% indicate highly favorable unit economics and efficient cost structure for current activities. That margin cushion supports future scale-up economics, improving the odds that increased revenue from trials or partnerships can translate into positive operating leverage over time.
Read all positive factors
Alterity Therapeutics (ATHE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$75.88M
Dividend YieldN/A
Average Volume (3M)13.05K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue GrowthN/A
EPS Growth63.31%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.96
Shares Outstanding3,625,148
10 Day Avg. Volume16,981
30 Day Avg. Volume13,055
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue12.74
Enterprise Value/Gross Profit13.16
Enterprise Value/Ebitda-2.46
Forecast
1Y Price Target
$12.00Price Target Upside238.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$3.44M
Alterity Therapeutics Business Overview & Revenue Model
Company Description
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent e...
How the Company Makes Money
null...
Alterity Therapeutics Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.83M | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M |
| Gross Profit | 3.71M | 5.31M | 3.80M | 3.63M | 4.76M | 3.98M |
| EBITDA | -19.87M | -14.63M | -19.57M | -14.60M | -17.39M | -15.16M |
| Net Income | -14.41M | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M |
Balance Sheet | ||||||
| Total Assets | 56.86M | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 49.15M | 40.66M | 12.64M | 15.77M | 34.81M | 28.12M |
| Total Debt | 98.35K | 155.46K | 159.04K | 210.38K | 117.49K | 65.65K |
| Total Liabilities | 2.65M | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M |
| Stockholders Equity | 54.21M | 42.40M | 13.80M | 22.81M | 35.47M | 30.47M |
Cash Flow | ||||||
| Free Cash Flow | -2.36M | -11.45M | -12.61M | -20.04M | -12.43M | -17.34M |
| Operating Cash Flow | -12.78M | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M |
| Investing Cash Flow | -137.62K | -7.50M | -5.72K | -36.46K | -89.15K | -10.47K |
| Financing Cash Flow | 44.09M | 39.67M | 9.22M | 124.34K | 16.30M | 36.69M |
Alterity Therapeutics Technical Analysis
Positive
3.55
Price Trends
4.24
Negative
3.83
Positive
3.89
Positive
Market Momentum
-0.05
Negative
51.69
Neutral
23.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATHE, the sentiment is Positive. The current price of 3.55 is below the 20-day moving average (MA) of 4.10, below the 50-day MA of 4.24, and below the 200-day MA of 3.89, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 51.69 is Neutral, neither overbought nor oversold. The STOCH value of 23.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATHE.
Alterity Therapeutics Risk Analysis
Alterity Therapeutics disclosed 44 risk factors in its most recent earnings report. Alterity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alterity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $75.88M | -6.91 | -30.19% | ― | ― | 63.31% | |
46 Neutral | $94.51M | -2.33 | -72.78% | ― | ― | 73.91% | |
43 Neutral | $15.65M | -0.39 | -226.10% | ― | ― | 71.62% | |
42 Neutral | $193.58M | -43.39 | -131.18% | ― | ― | -36.64% |
* Healthcare Sector Average
ATHE
Alterity Therapeutics
4.21
-0.21
-4.75%
CVM
Cel-Sci
1.08
-1.42
-56.80%
XBIT
XBiotech
2.34
-0.40
-14.60%
KLRS
Kalaris Therapeutics
4.33
1.66
62.17%
UNCY
Unicycive Therapeutics
7.25
-0.29
-3.85%
Alterity Therapeutics Corporate Events
Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
Jun 9, 2026
Alterity Therapeutics, which operates from Melbourne and San Francisco, is advancing a pipeline that centers on ATH434 for MSA, a rare and rapidly progressive Parkinsonian disorder with no approved disease-modifying therapies. Its Phase 2 program ...
Alterity Therapeutics Data Underpin Phase 3 Advancement of ATH434 in Multiple System Atrophy
May 19, 2026
On May 19, 2026, Alterity Therapeutics reported new clinical and imaging data for ATH434 in Multiple System Atrophy, presented across three medical conferences, which collectively support advancing the candidate to Phase 3 development. Analyses fr...
Alterity Therapeutics Files May 2026 Form 6-K, Releases New Corporate Presentation
May 12, 2026
On May 12, 2026, Alterity Therapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of May as a foreign private issuer. The filing incorporates certain existing registration statements by reference and primarily ...
Alterity Therapeutics Highlights MRI Biomarker Breakthrough as It Prepares Phase 3 MSA Program
May 11, 2026
On 11 May 2026, Alterity Therapeutics reported new peer-reviewed data in NeuroImage showing that quantitative susceptibility mapping MRI can identify disease-specific iron accumulation in Multiple System Atrophy, distinguish MSA from ParkinsonR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.